Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial

被引：0
|
作者：
Celine Busard
Stef Menting
SJ van Bezooijen
Juul van den Reek
Barbara Hutten
Errol Prens
Elke de Jong
Martijn van Doorn
Phyllis Spuls
机构：
[1] Academic Medical Center,Department of Dermatology
[2] Erasmus University Medical Center,Department of Dermatology
[3] Radboud University Medical Center,Department of Dermatology
[4] Academic Medical Center,Department of Clinical Epidemiology, Biostatistics and Bioinformatics
来源：
Trials | / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
    C. I. Busard
    S. P. Menting
    J. S. van Bezooijen
    J. M. van den Reek
    B. A. Hutten
    E. P. Prens
    E. M. de Jong
    M. B. van Doorn
    P. I. Spuls
    Trials, 18
  • [2] Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
    Busard, Celine
    Menting, Stef
    van Bezooijen, Sun-Jine
    van den Reek, Juul
    Hutten, Barbara
    Prens, Errol
    de Jong, Elke
    van Doorn, Martijn
    Spuls, Phyllis
    TRIALS, 2017, 18
  • [3] Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial (vol 18, 52, 2017)
    Busard, Celine
    Menting, Stef
    van Bezooijen, S. J.
    van den Reek, Juul
    Hutten, Barbara
    Prens, Errol
    de Jong, Elke
    van Doorn, Martijn
    Spuls, Phyllis
    TRIALS, 2017, 18
  • [4] Optimizing adalimumab treatment in psoriasis with concomitant methotrexate: a randomized controlled trial
    Van der Kraaij, G.
    Busard, C.
    van den Reek, J.
    Menting, S.
    de Jong, E.
    de Kort, W.
    Lambert, J.
    Spuls, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 25 - 26
  • [5] NSAIDs in sciatica (NIS): study protocol for an investigator-initiated multicentre, randomized placebo-controlled trial of naproxen in patients with sciatica
    Grovle, Lars
    Hasvik, Eivind
    Holst, Rene
    Haugen, Anne Julsrud
    TRIALS, 2022, 23 (01)
  • [6] NSAIDs in sciatica (NIS): study protocol for an investigator-initiated multicentre, randomized placebo-controlled trial of naproxen in patients with sciatica
    Lars Grøvle
    Eivind Hasvik
    Rene Holst
    Anne Julsrud Haugen
    Trials, 23
  • [7] The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial
    Lajevardi, Vahide
    Hallaji, Zahra
    Daklan, Soroush
    Abedini, Robabeh
    Goodarzi, Azadeh
    Abdolreza, Mona
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2015, 54 (01) : 95 - 101
  • [8] SWE and SMI ultrasound techniques for monitoring needling treatment of ankylosing spondylitis: study protocol for a single-blinded randomized controlled trial
    Wang, Mengyu
    Fu, Wen
    Meng, Lingcui
    Liu, Jia
    Wu, Lihua
    Peng, Yingjun
    Li, Ziping
    TRIALS, 2021, 22 (01)
  • [9] SWE and SMI ultrasound techniques for monitoring needling treatment of ankylosing spondylitis: study protocol for a single-blinded randomized controlled trial
    Mengyu Wang
    Wen Fu
    Lingcui Meng
    Jia Liu
    Lihua Wu
    Yingjun Peng
    Ziping Li
    Trials, 22
  • [10] Efficacy and safety of iloprost in patients with septic shock-induced endotheliopathy-Protocol for the multicenter randomized, placebo-controlled, blinded, investigator-initiated trial
    Bestle, Morten H.
    Clausen, Niels E.
    Soe-Jensen, Peter
    Kristiansen, Klaus T.
    Lange, Theis
    Johansson, Par, I
    Stensballe, Jakob
    Perner, Anders
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2020, 64 (05) : 705 - 711
12345